„At all times, our top priority was to protect the well-being of our employees while ensuring an uninterrupted supply of our medicines for patients.“, said our CEO Gabriel Baertschi in the new Grünenthal Report with a view to the challenges posed by Covid-19. „I am proud of the agility, solidarity and teamwork that our teams showed to achieve this important goal.“

 

The Grünenthal Report provides an up-to-date overview of all important areas of our company, from strategy, to our research and development and our corporate culture, as well as our product portfolio and our financial results. It becomes clear that we have achieved a lot in the past one and a half years. During the Corona pandemic, for example, we were able to maintain our production of medicines without restrictions in the interest of the many patients with chronic pain worldwide - a great success that was only possible thanks to the outstanding commitment of our employees. We were also able to achieve a consolidated profit of 1.280 billion euros and more than double our adjusted EBITDA from 129 million euros in 2017 to now 338 million euros in 2020. In our step onto the capital market, we also received convincing credit ratings.

 

In the recent years, Grünenthal has invested around 1,3 billion euros in the acquisition of established and high-quality product brands. At the same time, we have further expanded our research pipeline with three promising Phase-III and two Phase-I projects since 2020.

We have also successfully developed our corporate culture. In 2020, for example, we achieved our highest rating in the Great Place to Work® survey. 81 percent of the participating employees stated that Grünenthal is a great place to work. Our scores improved in all dimensions across all regions with an increase in the overall Engagement by 9 percent compared to 2017.

The publication is also dedicated to our commitment to environmental, social and responsible corporate governance and underlines Grünenthal's claim to meet the highest ethical standards at all times on topics such as the responsible use of opioids in pain therapy, compliance or environmental sustainability.

Last but not least, our 75th company anniversary is also appropriately honoured in this year's brochure, not only with regard to the graphic design, but also, for example, in the form of a greeting by the Chairman of our Supervisory Board Prof. Dr. Wilhelm Moll on the occasion of the anniversary, in which Grünenthal's development into today's highly innovative research-based pharmaceutical company with around 4,500 employees worldwide is outlined.

Click here for the English online version of the Grünenthal Report 2020/21.